tiprankstipranks
Trending News
More News >
ImmunityBio (IBRX)
NASDAQ:IBRX
Advertisement

ImmunityBio (IBRX) AI Stock Analysis

Compare
1,487 Followers

Top Page

IBRX

ImmunityBio

(NASDAQ:IBRX)

Rating:52Neutral
Price Target:
$3.00
▲(4.90%Upside)
ImmunityBio's overall stock score is influenced primarily by its financial struggles, including high leverage and negative cash flows, posing significant risks. However, the recent corporate event provides a positive outlook on liquidity and potential growth from clinical advancements.
Positive Factors
Global Strategy
The U.K. approval marks a key international milestone for Anktiva, representing a significant step in ImmunityBio's global strategy and affirming the strength of Anktiva’s underlying data.
Market Penetration
The U.K. authorization not only creates an incremental revenue opportunity but also establishes a foothold for broader EU market penetration, positioning Anktiva as a differentiated immunotherapy platform beyond the U.S. system.
Sales Growth
The market-driven pricing environment and rapid payer engagement in the U.S. have fueled strong early adoption and sales growth for Anktiva.
Negative Factors
Development Challenges
For small or cash-limited biotech companies, addressing an RTF can be especially challenging if major development work is needed.
Regulatory Challenges
ImmunityBio announced it received a surprising Refusal to File (RTF) letter from the FDA regarding its supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC patients with papillary-only disease.
Regulatory Uncertainty
The RTF letter introduces regulatory uncertainty, despite the identical treatment protocol between CIS and papillary cohorts.

ImmunityBio (IBRX) vs. SPDR S&P 500 ETF (SPY)

ImmunityBio Business Overview & Revenue Model

Company DescriptionImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
How the Company Makes MoneyImmunityBio generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of products developed using ImmunityBio's proprietary technologies. Additionally, the company may secure funding and grants from governmental and non-governmental organizations to support its research and development activities. As a clinical-stage company, ImmunityBio does not yet derive significant revenue from product sales, as its therapies are still in various stages of clinical trials and regulatory approval processes.

ImmunityBio Financial Statement Overview

Summary
ImmunityBio is facing significant financial challenges, including persistent losses, high leverage, negative cash flows, and negative equity. Revenue growth is present but overshadowed by substantial operating cash flow deficits and dependence on external financing.
Income Statement
35
Negative
ImmunityBio has shown some revenue growth in the latest year, with revenue increasing from $622,000 to $14.7 million. However, the company has been consistently unprofitable, with negative net profit margins and EBIT margins over the years. The gross profit margin remains positive, but the high levels of operating losses and negative EBITDA indicate significant profitability challenges.
Balance Sheet
30
Negative
The company's balance sheet shows high leverage, with total liabilities exceeding total assets, resulting in negative stockholders' equity. This poses a risk for financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, and the negative return on equity further highlights profitability issues.
Cash Flow
40
Negative
ImmunityBio's cash flow statement reflects substantial operating cash flow deficits, which have worsened over the years. The free cash flow remains negative, indicating ongoing challenges in generating cash from operations. Although the company has raised financing in previous years, the consistent negative free cash flow poses a risk to sustainability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.74M622.00K240.00K934.00K605.00K
Gross Profit-2.81M622.00K-23.95M934.00K-8.54M
EBITDA-241.76M-436.18M-335.51M-315.38M-187.93M
Net Income-413.56M-583.20M-417.32M-349.85M-224.19M
Balance Sheet
Total Assets382.93M504.45M362.36M468.91M221.38M
Cash, Cash Equivalents and Short-Term Investments149.81M266.46M107.18M317.12M96.06M
Total Debt504.17M726.72M723.77M645.66M275.55M
Total Liabilities871.06M1.09B812.18M712.82M339.87M
Stockholders Equity-488.13M-586.99M-447.33M-242.17M-119.81M
Cash Flow
Free Cash Flow-398.12M-397.34M-436.90M-307.98M-173.39M
Operating Cash Flow-391.24M-366.76M-337.51M-274.42M-171.72M
Investing Cash Flow-12.25M-30.47M27.30M-84.89M-19.81M
Financing Cash Flow281.63M558.34M233.61M505.44M150.68M

ImmunityBio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.86
Price Trends
50DMA
2.81
Positive
100DMA
2.75
Positive
200DMA
3.26
Negative
Market Momentum
MACD
0.02
Negative
RSI
52.22
Neutral
STOCH
76.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Positive. The current price of 2.86 is above the 20-day moving average (MA) of 2.77, above the 50-day MA of 2.81, and below the 200-day MA of 3.26, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 52.22 is Neutral, neither overbought nor oversold. The STOCH value of 76.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRX.

ImmunityBio Risk Analysis

ImmunityBio disclosed 95 risk factors in its most recent earnings report. ImmunityBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ImmunityBio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$2.56B13.3829.11%29.97%178.11%
64
Neutral
$1.77B-5.78%25.50%64.63%
56
Neutral
$2.11B-38.04%-82.38%-164.76%
54
Neutral
$1.79B-70.58%100.03%64.22%
52
Neutral
$7.61B0.11-63.03%2.07%16.35%0.29%
52
Neutral
$2.66B78.99%10238.41%47.67%
45
Neutral
$3.13B-62.46%-43.10%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IBRX
ImmunityBio
2.86
-2.57
-47.33%
CPRX
Catalyst Pharma
20.97
3.49
19.97%
IMVT
Immunovant
16.95
-12.14
-41.73%
ARQT
Arcutis Biotherapeutics
14.86
5.29
55.28%
BEAM
Beam Therapeutics
21.72
-10.32
-32.21%
IMCR
Immunocore Holdings
35.17
-4.57
-11.50%

ImmunityBio Corporate Events

Private Placements and FinancingFinancial Disclosures
ImmunityBio Announces $80 Million Securities Purchase
Positive
Jul 25, 2025

On July 24, 2025, ImmunityBio, Inc. announced a securities purchase agreement to sell 29,629,632 shares of its common stock and warrants for an additional 29,629,632 shares, generating approximately $80 million in gross proceeds. The offering is expected to close around July 28, 2025, with Piper Sandler & Co. as the exclusive placement agent. In its Q2 2025 financial results, ImmunityBio reported a 60% increase in revenue to $26.4 million, driven by strong sales of ANKTIVA in BCG-unresponsive bladder cancer. The company also highlighted significant clinical progress, including the initiation of a randomized trial for lung cancer and regulatory discussions on lymphopenia and papillary NMIBC treatments.

The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
ImmunityBio Approves 2025 Equity Incentive Plan
Neutral
Jun 20, 2025

On June 18, 2025, ImmunityBio, Inc. held its Annual Meeting of Stockholders, where the 2025 Equity Incentive Plan was approved, replacing the 2015 Plan. This strategic move aims to better compete for and motivate key talent through equity-based awards, aligning the interests of employees and stockholders. Additionally, eight directors were re-elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for 2025 was ratified.

The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025